Recruiting

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.

ClinicalTrials.gov IDNCT05196087

PhaseNot Applicable

Enrollment500

SponsorUniversity Health Network, Toronto

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor

About this study

Primary outcomes

Change from Baseline in ctDNA collected from biospecimens (Through study completion, an average of 4 years)

Eligibility information

Inclusion Criteria: 1. Patients with histological confirmation of a solid tumor. 2. Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment. 3. Patient must be ≥ 18 years old. 4. All patients must have signed and dated an informed consent form. Exclusion Criteria: None

Study locations

Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9 Canada

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.